CHRISTOPHER MANLEY and KRISTEN SCULLY MANLEY joined Fox Chase Cancer Center. Christopher Manley will serve as the director of interventional pulmonology in the Department of Medicine, and Kristen Scully Manley will serve as a hospitalist in the department of medicine. “Dr. Manley’s expertise in pulmonary medicine makes him the perfect candidate for our new director […]
PIERRE MASSION will direct the Vanderbilt-Ingram Cancer Center’s Cancer Early Detection and Prevention Initiative. Massion is the Cornelius Vanderbilt Professor of Medicine, an Ingram Professor of Cancer Research and co-leader of the VICC Cancer Health Outcomes and Control Research Program. “The prevention of cancer and the development of more effective strategies to detect cancer precursors […]
THE UNIVERSITY OF PITTSBURGH CANCER INSTITUTE, partnered with UPMC CancerCancer, received a contract from NCI to perform preclinical research for the development of new cancer drugs. This commitment could bring up to $10 million in research projects to UPCI over the next five years. Julie Eiseman, professor of pharmacology and chemical biology, and Jan Beumer, […]
DANA-FARBER CANCER INSTITUTE received $100 million for a portion of its interest in royalties related to its Programmed Death Ligand-1 intellectual property. CPPIB Credit Europe S.à r.l., a wholly owned subsidiary of Canada Pension Plan Investment Board, paid $100 million upfront, and has committed to pay up to $68 million in additional payments, subject to […]
Nature published an editorial supporting Kids vs. Cancer's bill to increase support for pediatric clinical trials.
Greg Curt died last Sunday. For us in oncology, this one was especially personal. He was a wonderful, generous young man. Greg was a beloved friend and colleague. He was an accomplished cancer researcher and leader in oncology who died of the disease we treat.
League tables like those published by U.S. News and World Report should probably be taken with a pinch of salt in any case, but it is the self-marketing of these tables that is just a bit problematic.
The U.S. News & World Report rankings of the best cancer hospitals for 2016 brought no great surprises. The top four remained unchanged from last year:
A phase III study evaluating Gazyva (obinutuzumab) plus CHOP chemotherapy in people with previously untreated diffuse large B-cell lymphoma did not meet its primary endpoint of progression-free survival compared to Rituxan (rituximab) plus CHOP chemotherapy, according to Genentech, a member of the Roche Group.
Positive results from a phase III trial in advanced colorectal cancer showed that Xilonix-treated patients with advanced disease and multiple symptoms known to inversely correlate with overall survival experienced a 76 percent relative increase in clinical response rate after eight weeks of therapy compared to placebo, at 33 percent vs. 19 percent, respectively (p=.0045).
